Stock Events

Stock Events

Soleno Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, directly competing with Soleno's therapeutic areas.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, competing in the same therapeutic area as Soleno.
PTC Therapeutics
PTCT
Mkt Cap7.04B
PTC Therapeutics operates in the field of genetic disorders, including rare diseases, making it a direct competitor to Soleno Therapeutics.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its advanced therapies, competing in the same niche as Soleno.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, including treatments for rare diseases, overlapping with Soleno's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, targeting genetic and rare diseases, which puts it in competition with Soleno.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing technology, which has applications in treating rare diseases, potentially competing with Soleno's therapeutic approach.

About

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Show more...
CEO
Dr. Anish Bhatnagar M.D.
Employees
115
Country
United States
ISIN
US8342032005

Listings

STU
DE
6XC.STU
MU
DE
6XC1.MU
BOATS
BOATS
SLNO.BOATS

0 Comments

Share your thoughts

FAQ

What is Soleno Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Soleno Therapeutics stocks are traded under the ticker 6XC1.MU.
How many employees does Soleno Therapeutics have?▼
As of July 22, 2026, the company has 115 employees.
In which sector is Soleno Therapeutics located?▼
Soleno Therapeutics operates in the Health & Wellness sector.
When did Soleno Therapeutics complete a stock split?▼
The last stock split for Soleno Therapeutics was on August 26, 2022 with a ratio of 1:15.
Where is Soleno Therapeutics headquartered?▼
Soleno Therapeutics is headquartered in Redwood City, United States.